A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) (NCT03401788)

🧪 Interventions in This Study

• Belzutifan (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (11 Sites)

• National Institutes of Health Clinical Center — Bethesda, Maryland
• Massachusetts General Hospital — Boston, Massachusetts
• University of Michigan — Ann Arbor, Michigan
• University of Pennsylvania Medical Center — Philadelphia, Pennsylvania
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
• Vanderbilt Medical Center — Nashville, Tennessee
• MD Anderson Cancer Center — Houston, Texas
• Huntsman Cancer Institute — Salt Lake City, Utah
• Aarhus University Hospital — Aarhus,
• Hospital Georges Pompidou — Paris,
• Cambridge University Hospital — Cambridge,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All VHL - Von Hippel-Lindau Syndrome clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.